Xponance Inc. Sells 1,189 Shares of Illumina, Inc. (NASDAQ:ILMN)

Xponance Inc. decreased its holdings in shares of Illumina, Inc. (NASDAQ:ILMN) by 4.6% during the second quarter, according to its most recent filing with the SEC. The firm owned 24,937 shares of the life sciences company’s stock after selling 1,189 shares during the period. Xponance Inc.’s holdings in Illumina were worth $2,603,000 at the end of the most recent reporting period.

A number of other institutional investors have also added to or reduced their stakes in the business. Gryphon Financial Partners LLC increased its holdings in shares of Illumina by 22.1% in the 4th quarter. Gryphon Financial Partners LLC now owns 1,807 shares of the life sciences company’s stock valued at $252,000 after acquiring an additional 327 shares during the period. Cambridge Investment Research Advisors Inc. grew its stake in Illumina by 134.1% in the fourth quarter. Cambridge Investment Research Advisors Inc. now owns 17,316 shares of the life sciences company’s stock valued at $2,411,000 after purchasing an additional 9,918 shares during the last quarter. Stifel Financial Corp raised its holdings in Illumina by 6.6% in the fourth quarter. Stifel Financial Corp now owns 52,447 shares of the life sciences company’s stock worth $7,303,000 after purchasing an additional 3,269 shares in the last quarter. Treasurer of the State of North Carolina lifted its position in shares of Illumina by 1.0% during the fourth quarter. Treasurer of the State of North Carolina now owns 72,176 shares of the life sciences company’s stock valued at $10,050,000 after buying an additional 690 shares during the last quarter. Finally, Dorsey & Whitney Trust CO LLC bought a new stake in shares of Illumina in the 4th quarter valued at about $333,000. Hedge funds and other institutional investors own 89.42% of the company’s stock.

Illumina Stock Performance

ILMN opened at $132.27 on Friday. The company has a current ratio of 1.11, a quick ratio of 0.86 and a debt-to-equity ratio of 1.04. The firm’s 50-day moving average price is $125.71 and its 200 day moving average price is $120.42. The firm has a market capitalization of $21.07 billion, a PE ratio of -16.23 and a beta of 1.15. Illumina, Inc. has a twelve month low of $89.00 and a twelve month high of $148.19.

Illumina (NASDAQ:ILMN) last issued its earnings results on Tuesday, August 6th. The life sciences company reported $0.36 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.12 by $0.24. Illumina had a positive return on equity of 3.08% and a negative net margin of 68.73%. The company had revenue of $1.11 billion during the quarter, compared to analysts’ expectations of $1.09 billion. During the same period in the prior year, the business earned $0.32 EPS. The firm’s quarterly revenue was down 5.4% on a year-over-year basis. As a group, sell-side analysts expect that Illumina, Inc. will post 3.63 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts recently commented on the stock. Scotiabank reduced their price objective on shares of Illumina from $176.00 to $164.00 and set a “sector outperform” rating for the company in a research note on Thursday, August 15th. Jefferies Financial Group initiated coverage on Illumina in a research report on Monday, June 3rd. They set a “hold” rating and a $115.00 price target on the stock. Robert W. Baird increased their price objective on Illumina from $119.00 to $124.00 and gave the company a “neutral” rating in a report on Wednesday, August 7th. Piper Sandler dropped their target price on Illumina from $200.00 to $195.00 and set an “overweight” rating on the stock in a research note on Tuesday, August 13th. Finally, Daiwa America raised Illumina to a “strong-buy” rating in a research report on Friday, August 16th. One equities research analyst has rated the stock with a sell rating, nine have given a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, Illumina currently has a consensus rating of “Moderate Buy” and a consensus target price of $151.05.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.